Jose Chamorro
Adult Health · Miami, FLNPI 1376978460
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,171 of the $15,274 with a category attached, or 73.1%. It is spread thinly across 35 manufacturers, the largest accounting for just 21.1%. 2025 is the largest year on record at $4,518, 3.6 times the $1,253 reported in 2021. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 419 payments — averaging $36.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$3K
- Medtronic$3K
- AstraZeneca$2K
- Abbott$2K
- Boston Scientific$1K
- Impulse Dynamics (USA) Inc.$670
- plus $5K from 29 others
What the payments were for
- Travel & lodging$3,92126%
- Food & beverage$11,17173%
- Education$1821%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 70 | $3,226 |
| Medtronic | 56 | $2,662 |
| AstraZeneca | 41 | $1,602 |
| Abbott | 54 | $1,546 |
| Boston Scientific | 8 | $1,019 |
| Impulse Dynamics (USA) Inc. | 12 | $670 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $509 |
| Johnson & Johnson | 17 | $432 |
| E.r. Squibb & Sons, L.L.C. | 9 | $391 |
| Amgen | 21 | $372 |
| Novo Nordisk | 21 | $366 |
| Actelion Pharmaceuticals US, Inc. | 8 | $311 |
| Novartis | 15 | $309 |
| Pfizer | 16 | $308 |
| Merck | 11 | $216 |
| Scpharmaceuticals Inc. | 4 | $212 |
| Bayer | 8 | $175 |
| Lexicon Pharmaceuticals, Inc. | 1 | $122 |
| Bridgebio Pharma, Inc. | 4 | $120 |
| Kestra Medical Technology Services, Inc. | 4 | $84 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Amarin Pharma, Inc. | 3 | $58 |
| Baxter Healthcare | 3 | $56 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $50 |
| Alnylam Pharmaceuticals Inc. | 2 | $50 |
| Atricure, Inc. | 2 | $45 |
| Irhythm Technologies, Inc. | 2 | $45 |
| Philips North America LLC | 2 | $44 |
| Sumitomo Pharma America, Inc. | 2 | $42 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $39 |
| Angiodynamics, Inc. | 1 | $33 |
| Boehringer Ingelheim | 1 | $29 |
| Lilly USA, LLC | 2 | $28 |
| Endotronix, Inc. | 1 | $23 |
| Tactile Systems Technology Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,274 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 44 | $37,017 |
| EliquisApixaban | 36 | $32,812 |
| FarxigaDapagliflozin Propanediol | 13 | $13,147 |
| Metoprolol Succinate | 43 | $498 |
| Metoprolol Tartrate | 19 | $169 |
| Furosemide | 15 | $99 |
| Losartan Potassium | 18 | $63 |
| Carvedilol | 13 | $58 |
| Rosuvastatin Calcium | 17 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $309 | $37,01744 claims |
| PfizerEliquis | $308 | $32,81236 claims |
| AstraZenecaFarxiga | $1,602 | $13,14713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Miami
- Norma SolisMiami$150K
- Jeffrey HernandezMiami$122K
- Kristen NievesMiami$16K
- Wendy KaysMiami$13K
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Ashley PontenbergWinter Park$136K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.